Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 24:38:100490.
doi: 10.1016/j.jctube.2024.100490. eCollection 2025 Feb.

Buruli ulcer: Current landscape, challenges, and future directions

Rie R Yotsu  1   2   3 , Richard O Phillips  4   5
Affiliations
Editorial

Buruli ulcer: Current landscape, challenges, and future directions

Rie R Yotsu et al. J Clin Tuberc Other Mycobact Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. World Health Organization. Buruli ulcer 2024. https://www.who.int/data/gho/data/themes/topics/buruli-ulcer (accessed August 1, 2024 2024).
    1. Tchatchouang S., Andre Mbongue Mikangue C., Kenmoe S., et al. Systematic review: Global host range, case fatality and detection rates of Mycobacterium ulcerans in humans and potential environmental sources. J Clin Tuberc Other Mycobact Dis. 2024;36 - PMC - PubMed
    1. Phillips R., Horsfield C., Kuijper S., et al. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol. 2005;43(8):3650–3656. - PMC - PubMed
    1. Sakakibara Y., Konishi M., Ueno T., et al. Pilot use of a mycolactone-specific lateral flow assay for Buruli ulcer: a case report from Japan. J Clin Tuberc Other Mycobact Dis. 2024;36 - PMC - PubMed
    1. Phillips R.O., Robert J., Abass K.M., et al. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet. 2020;395(10232):1259–1267. - PMC - PubMed

Publication types

LinkOut - more resources